The Reaction Biology Leadership Team

Matthew Oristano CEO Reaction Biology
Matthew Oristano Chief Executive Officer
Woodbridge, USA
Languages: English

Matthew Oristano

Chief Executive Officer

Mr. Oristano is the President and CEO of Reaction Biology since 2004.  He has led strategy and finance of the company and negotiated the acquisition of ProQinase in 2019.  In addition to his position at RBC, he serves on the board and is the audit committee chairman of Spōk (Nasdaq: SPOK).  From 1993 to 1999, Mr. Oristano was Chairman and CEO of People’s Choice TV Corp, a public wireless communications company, which he founded in 1988 and sold to Sprint in 1999.  He has extensive experience in corporate strategy, management, finance, marketing, and regulatory compliance.  Mr. Oristano has a degree in physics from Rennselaer Polytechnic Institute.

Matthew Oristano CEO Reaction Biology
Haiching Ma
Haiching Ma, PhD Chief Scientific Officer
Malvern, USA
Languages: English, Chinese

Haiching Ma, PhD

Chief Scientific Officer

Dr. Ma joined Reaction Biology in 2001 as employee number one. He is the Chief Science Officer, where he developed and implemented the current Reaction Biology technology and service platforms. Dr. Ma is the Principal Investigator for multiple SBIR awards and an RO1 award from NIH all Reaction Biology totaling over $12 million, and which cover research topics including assay development for human kinome and epigenome targets, toxicity predictions, chemical microarray HTS and cell death prevention that reduce side effects from radiation therapies. Dr. Ma is serving as a national Steering Committee Member for the NIH National Cancer Institute's Chemical Biology Consortium. He received his Ph.D. in Pharmacology from the Medical School of The University of Pennsylvania and continued his postdoc training there in the Institute for Medicine and Engineering.

Haiching Ma
Sebastian Dempe
Sebastian Dempe, PhD Chief Executive Officer Germany
Freiburg, Germany
Languages: German, English, French

Sebastian Dempe, PhD

Chief Executive Officer Germany

Sebastian Dempe is biologist by training and received his doctorate degree from the German Cancer Research Center/ University of Heidelberg in 2010 where he was exploiting the capacity of parvovirus H1, currently tested in clinical studies, for the virotherapy of cancer using various preclinical research models. Starting his career in Business Development at ProQinase (2011-2014), he was later appointed as Executive Director Business Development of Crown Bioscience, Inc., leading the company’s European Business Development team until June 2019. Sebastian re-joined ProQinase as CEO/ Managing Director on July 01, 2019.

Sebastian Dempe
Robert Hartman, MSME
Robert Hartman, MSME Chief Information Officer
Malvern, USA
Languages: English

Robert Hartman, MSME

Chief Information Officer

Robert Hartman joined Reaction Biology in 2009. Mr. Hartman developed and implemented the R-Net system, which converts unstructured laboratory documents into actionable data. This system drives automation, manages just-in-time inventory, performs statistical analysis, generates client and management reports, and serves as a job planning tool. Other systems designed and implemented at Reaction Biology by Mr. Hartman include database applications that integrate with client LIMS, software that converts client reports into neutral files or databases, and productivity tools that bi-directionally exchange data with client relationship management tools. Mr. Hartman has held the Director of Software Development role at several firms and has managed the development of several hundred commercial software development projects. Mr. Hartman holds a MS degree in Mechanical Engineering from Drexel University.

Robert Hartman, MSME
Goutham G. Reddy, JD
Goutham G. Reddy, JD General Counsel
Malvern, USA
Languages: English

Goutham G. Reddy, JD

General Counsel

Mr. Reddy joined Reaction Biology as General Counsel in 2018, having been its corporate counsel since 2013.  Prior to that, he was Corporate Counsel at Strategic Diagnostics and Senior Counsel at Cigna. Mr. Reddy oversees all legal affairs of Reaction Biology and its subsidiaries, in addition to assisting in M&A transactions. Mr. Reddy received his Doctor of Law degree from Case Western Reserve University School of Law. He also has a degree in biology from Kent State University.

Goutham G. Reddy, JD

Business Development Managers

Reaction Biology is supported by a global team of business development representatives to ensure timely and personal communication with our customers in any time zone.

Curious? Please visit our BD page and find out who is located near you.

Scientific Leadership

Kurumi Horiuchi, PhD
Kurumi Horiuchi, PhD
Director of Biochemistry, USA
Languages: English, Japanese

Kurumi Horiuchi, PhD

Director of Biochemistry, USA

Kurumi Horiuchi, PhD joined Reaction Biology in 2004. She is responsible for assay development and handles orders for custom biochemical assay development, including kinetic analysis for mechanism of action studies. Previously, she held positions as an enzymologist in the Enzymology Department at DuPont Merck, DuPont Pharmaceuticals, and Bristol-Myers Squibb, where she was involved in all stages of drug discovery, from target identification to clinical studies, including HTS, SAR, and mode of action studies for lead compounds. As an enzymologist, she focused specifically on difficult enzymes and problem compounds and developed assays for kinetic analyses in areas including cancer, inflammatory diseases, cardiovascular diseases, and antibacterial and antiviral therapies. Dr. Horiuchi holds a Ph.D. in Biophysics from the School of Science and Engineering at Waseda University. She completed postdoctoral training at the University of Pennsylvania, with a focus on smooth muscle regulation.

Ekaterina Kuznetsova image
Ekaterina Kuznetsova, PhD
Ekaterina Kuznetsova, PhD
Director of Product Development, USA
Languages: English, Russian

Ekaterina Kuznetsova, PhD

Director of Product Development, USA

Ekaterina Kuznetsova, PhD joined Reaction Biology in 2014, concentrating on developing new assays for epigenetic targets, and leading Reaction Biology’s protein production group. Dr. Kuznetsova has a broad background in enzymatic assay development and has intensive experience in working with epigenetic targets, as well as other enzymatic families. Dr. Kuznetsova’s research is published in a number of peer-reviewed journals, including the Journal of Biological ChemistryNature Biotechnology, and ACS Medicinal Chemistry Letters. She received her Ph.D. from the University of Toronto in 2009, focusing on areas of proteomics and biochemistry. She continued her training as a postdoctoral scientist at the Structural Genomics Consortium (MBB/Karolinska Institute, Sweden), working on the evaluation of PARP inhibitors. After that, Dr. Kuznetsova worked at SGC Toronto, University of Toronto as a Research Associate concentrating on epigenetic assay development and HTS for early-stage drug discovery.

Michael Kubbutat, PhD
Michael Kubbutat, PhD
Michael Kubbutat, PhD
Head of Biochemical Drug Discovery and Head of Drug Development, Germany
Languages: English, German

Michael Kubbutat, PhD

Head of Biochemical Drug Discovery and Head of Drug Development, Germany


Michael Kubbutat studied biology and cell biology and obtained his Ph.D. at the Research Center Borstel, Germany. In 1994, Michael Kubbutat started post-doctoral studies at the Ludwig Institute for Cancer Research (London, UK) in the group of Prof. Karen Vousden. Together with the group of Prof. Vousden, he moved in 1995 to the National Cancer Institute, Frederick, USA. In 1999 he joined the Tumor Biology Center Freiburg, Germany first as a group leader (Molecular Cell Biology), and later as Head of the Target Identification & Validation Department. In 2001 he joined ProQinase as Head of R&D. Since 2010, Michael Kubbutat is Head of Biochemical Drug Discovery & Head of Drug Development at Reaction Biology Europe.

Holger Weber
Holger Weber, PhD
Holger Weber, PhD
Head of In Vivo Pharmacology, Project Management & Internal Innovations
Languages: English, German

Holger Weber, PhD

Head of In Vivo Pharmacology, Project Management & Internal Innovations


Holger Weber studied biology and obtained his Ph.D. at the Max-Planck Institute for Immunobiology in Freiburg, Germany. In 2001 he joined the research group of Prof. Augustin at the Tumor Biology Center, Freiburg. The scientific focus and interest during that time was the field of angiogenesis, first as a Post-Doc, later as a group leader. In 2007 he left basic research and started to work at ProQinase as a group leader in the Department of Cellular Drug Discovery. Since 2014, Holger Weber is Head of In Vivo Pharmacology responsible for the resorts Project Management and Internal Innovations.

Cynthia Obodozie
Cynthia Obodozie, DVM, PhD
Cynthia Obodozie, DVM, PhD
Head of In Vivo Pharmacology
Project Management & Animal Affairs
Languages: English, German

Cynthia Obodozie, DVM, PhD

Head of In Vivo Pharmacology
Project Management & Animal Affairs


After completing her veterinary studies in Berlin, Germany, Cynthia wrote her doctoral thesis at the pharmaceutical company Bayer (formerly Schering AG, Berlin) in the preclinical oncology department in the field of antiestrogens and their anti-tumor effects on endometrial cancer. As a postdoc, Cynthia worked for 3 years at the KTB Tumorforschungs GmbH in Freiburg, Germany, in the angiogenesis research department with a focus on tumor angiogenesis. Then she switched to ProQinase GmbH and worked as a senior scientist and later as a group leader in the in vivo pharmacology department. In this role, she is involved in the implementation and supervision of in vivo studies as well as customer communication and advice. In the additional position as Head of Animal facility, she takes care of the concerns of the animals, the equipment, and the staff as well as the official regulations regarding animal studies. In her role as Head of in vivo Pharmacology, she manages the department in a dual leadership and thus influences the direction and future goals of the department.

Bob Dougherty image
Bob Dougherty, PhD
Bob Dougherty, PhD
Director of In Vitro Pharmacology, USA
Languages: English

Bob Dougherty, PhD

Director of In Vitro Pharmacology, USA

Robert Dougherty, PhD joined Reaction Biology in 2018, bringing 30 years of pharmacology experience with an emphasis on cell-based drug discovery.  Dr. Dougherty was previously Director of Discovery Biology for Jubilant Biosystems ion-channel group before it was acquired by Reaction Biology. Prior to that, he was the Director of Cellular Pharmacology for Amphora Discovery. He holds a Ph.D. in Pharmacology and Toxicology from Virginia Commonwealth University School of Medicine.

Jan Ehlert
Jan Ehlert, PhD
Jan Ehlert, PhD
Head of Cellular Drug Discovery, Germany
Languages: English, German

Jan Ehlert, PhD

Head of Cellular Drug Discovery, Germany

Jan Erik Ehlert is cell biologist by training and has gained his PhD at the Research Center Borstel, Germany, in the field of chemokine biology in innate immunology. During his Postdoc studies at the University of Michigan in Ann Arbor, he extended his scientific focus on the relevance of angiogenesis in lung cancer. In the year 2001, Jan Ehlert joined ProQinase as group leader in the field of target identification and validation in cancer biology. Since 2010, he is member of the management team at ProQinase as Head of the Department of Cellular Drug Discovery. His team is specialized on cellular assay systems in oncology, cellular screening and 3D assay systems. Jan Ehlert is co-inventor in several patents on compound classes issued to treat kinase-related cancer diseases.

Yangbo Feng
Yangbo Feng, PhD
Yangbo Feng, PhD
Director of Medicinal Chemistry and Director of Drug Discovery and Development, USA
Languages: English, Chinese

Yangbo Feng, PhD

Director of Medicinal Chemistry and Director of Drug Discovery and Development, USA

Yangbo Feng Ph.D. joined RBC in 2016. He provides medicinal chemistry advisory services to Reaction Biology customers. Dr. Feng has been the principal investigator on multiple research grants. Prior to joining Reaction Biology, Dr. Feng was Associate Director of Medicinal Chemistry at The Scripps Research Institute. He holds a Ph.D. in organic chemistry from UC San Diego.

Rebecca Eells, PhD
Rebecca Eells, PhD
Associate Director of Biophysics
Languages: English

Rebecca Eells, PhD

Associate Director of Biophysics

Rebecca Eels, PhD joined RBC in 2018 and is the head of the biophysical assay services. Her group has developed and performed SPR projects for customers covering a large number of drug targets, involving broad range therapeutic areas, including cancer, antiviruses, etc. Dr. Eels has a broad background in biophysical assay development, specializing in SPR. She holds a Ph.D. in Molecular Biophysics and Structural Biology from Carnegie Mellon University.

Jianghong Wu
Jianghong Wu, PhD
Jianghong Wu, PhD
Associate Director Of Cell Biology
Languages: English, Chinese

Jianghong Wu, PhD

Associate Director Of Cell Biology

Jianghong Wu, PhD joined RBC in 2012 and leads a team that performs kinase cell-based target engagement assays and other cell-based customer services. Dr. Wu has extensive experience in cell biology, molecular biology, and drug screening studies, and has over 20 years of research experience. He holds a Ph.D. degree in immunology from Nagoya University, Japan and did postdoctoral studies at the University of Toronto, and Thomas Jefferson University.

Claudia Pérez Ortega photograph
Claudia D. Pérez Ortega, PhD
Claudia D. Pérez Ortega, PhD
Associate Director of Kinase Services
Languages: English, Spanish

Claudia D. Pérez Ortega, PhD

Associate Director of Kinase Services

Claudia D. Pérez Ortega, PhD joined Reaction Biology in 2019 and oversees a team of project managers to lead and perform kinase customer service. Dr. Pérez Ortega has a strong background in Biochemistry, Enzymology, Molecular, and Cell biology and proven lab work experience. She joined Reaction Biology from DuPont Pioneer, and holds a Ph.D. degree in Biochemical Sciences from the Biotechnology Institute of Universidad Nacional Autónoma de México (UNAM) and did postdoc training at Universidad Nacional Autónoma in Madrid.

Earl Gordon, PhD
Earl Gordon, PhD
Manager, Ion Channel Services
Languages: English

Earl Gordon, PhD

Manager, Ion Channel Services

Earl Gordon joined Reaction Biology in 2018. He oversees the company’s ion channel assay facility with both automated and manual patch clamp services. Prior to joining Reaction Biology, Dr. Gordon was Senior Scientist with Jubilant Discovery Services, assisting customers with pre-IND ion channel assays, and before that led the electrophysiology group at Knopp Biosciences as they advanced their Kv7 ion channel modulator for epilepsy.  Dr. Gordon received a Ph.D. in Pharmacology from Cornell University.

Kayleigh McGovern-Gooch, PhD
Kayleigh McGovern-Gooch, PhD
Manager of the Non-Kinase Biochemical Group, USA
Languages: English

Kayleigh McGovern-Gooch, PhD

Manager of the Non-Kinase Biochemical Group, USA

Kayleigh McGovern-Gooch, PhD joined Reaction Biology in 2019, and manages all non-kinase assay activity, including a large number of fluorescent format assay groups such as HDAC, Protease, Deubiquitinase, Phosphatase, etc. She completed her graduate work at Syracuse University, where she developed novel activity assays and discovered small molecule inhibitors for ghrelin O-acyltransferase.

Board of Directors

Tom Petzinger, Jr.

Mr. Petzinger is CEO of LaunchCyte, a biotechnology development firm. Mr. Petzinger also serves as Chairman of Immunetrics Inc., Crystalplex Corp, Proteopure Inc., and Knopp Neurosciences. Prior to co-founding LaunchCyte, he spent 22 years at The Wall Street Journal, where he served as Washington economics editor, deputy Washington bureau chief, millennium editor, and weekly columnist. A Pulitzer nominee for numerous investigative stories, he has also written three best-selling business books. He received his B.S. in Journalism from Northwestern University, where he was a Richter International Scholar.

Michael Kramer

Based in New York City, Mr. Kramer has had long experience advising firms and governments worldwide on financial transactions totaling hundreds of billions of dollars. He is currently the Founding Partner of Ducera Partners LLC. Previously, he has been a senior partner at Perella Weinberg Partners, a member of the Management Committee at Greenhill & Co, and head of M&A and Financial Restructuring for the firm of Houlihan Lokey Howard & Zukin.

Jonathan Kaufman, PhD

Dr. Kaufman is the CEO of Lipella Pharmaceuticals, Inc. Prior to co-founding Lipella, Dr.Kaufman was Vice President and Chief Science Officer of LaunchCyte LLC, a biotechnology corporate incubator. At LaunchCyte, Dr. Kaufman was co-founder of Proteopure Inc. and Knopp Neuroscience Inc.; served as the founding President of Crystalplex Corp.; served on the Boards of Reaction Biology Corp., Crystalplex Corp., and Immunetrics Inc.; and served as Secretary of Reaction Biology Corp. Prior to joining LaunchCyte, Dr. Kaufman served on the New Technology Committee in the Chemical Manufacturing Division of Merck& Co., and also served as a consultant to GlaxoSmithKline in the department of bioinformatics. Dr. Kaufman received his MBA in Finance from the Wharton School, and his PhD in Biophysics from the University of Pennsylvania School of Medicine.

Matthew Oristano

Mr. Oristano is the President and CEO of Reaction Biology since 2004.  He has led strategy and finance of the company and negotiated the acquisition of ProQinase in 2019.  In addition to his position at RBC, he serves on the board and is the audit committee chairman of Spōk (Nasdaq: SPOK).  From 1993 to 1999, Mr. Oristano was Chairman and CEO of People’s Choice TV Corp, a public wireless communications company, which he founded in 1988 and sold to Sprint in 1999.  He has extensive experience in corporate strategy, management, finance, marketing, and regulatory compliance.  Mr. Oristano has a degree in physics from Rennselaer Polytechnic Institute.

Haiching Ma, PhD

Dr. Ma joined Reaction Biology in 2001 as employee number one. He is the Chief Science Officer, where he developed and implemented the current Reaction Biology technology and service platforms. Dr. Ma is the Principal Investigator for multiple SBIR awards and an RO1 award from NIH all Reaction Biology totaling over $12 million, and which cover research topics including assay development for human kinome and epigenome targets, toxicity predictions, chemical microarray HTS and cell death prevention that reduce side effects from radiation therapies. Dr. Ma is serving as a national Steering Committee Member for the NIH National Cancer Institute's Chemical Biology Consortium. He received his Ph.D. in Pharmacology from the Medical School of The University of Pennsylvania and continued his postdoc training there in the Institute for Medicine and Engineering.